LASIK induces visual improvements faster than LASEK

Article

Visual improvements for low myopia is significantly slower after LASEK than after LASIK, according to a study published in the February issue of the Journal of Refractive Surgery.

Visual improvements for low myopia is significantly slower after LASEK than after LASIK, according to a study published in the February issue of the Journal of Refractive Surgery.

Laura de Benito-Llopis and colleagues from the Vissum Corporación, Universidad de Alcalá and the Universidad Complutense, Madrid, Spain enrolled 79 eyes to the LASEK group and 79 eyes to the LASIK group in a prospective, interventional, non-randomized, observer-masked study. Each subject had myopia of < -2.50 D. Refractive analysis was performed preoperatively and one day, one week and one and three months postoperatively.

Postoperative uncorrected visual acuity (UCVA) was significantly lower in LASEK eyes at one and seven days postoperatively (p=0.0001). At one and three months, no significant differences were noted between the groups in UCVA, however, best spectacle corrected visual acuity (BSCVA) at three months was significantly better in LASEK eyes (p=0.01). The refractive error was similar in both groups (p=0.3).

The researchers found that, although postoperative UCVA was similar in both groups at three months, the LASEK subjects were slower in reaching this level.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.